Krivokhizhin Igor Viktorovich (full-time postgraduate student of the Department of Surgical Diseases of the Medical Institute of the Higher Educational Institution of the Khanty-Mansi Autonomous Okrug-Yugra "Surgut State University"
Oncologist BU "Surgut District Clinical Hospital" Russia, Surgut)
Parsadanyan Ararat Mikichovich (MD, Professor of the Department of Surgical Diseases of the Medical Institute of the Surgut State University, Surgut State University,
Chief Freelance Specialist Oncologist of the Surgut District Clinical Hospital, Surgut, Russia
)
Stepanyan Arus Araratovna (Oncologist BU "Surgut District Clinical Hospital" Russia, Surgut)
| |
Neoadjuvant drug therapy has become an integral part of the comprehensive treatment of breast cancer, especially with the HER2-positive biological subtype. Over the past few years, the drug tactics of early HER2+ breast cancer has gone through many stages, starting from the appointment of chemotherapy in patients with HER2+ status in the era of the absence of targeted agents, to the sequential administration of preoperative and postoperative anti-HER2 drugs in combination with chemotherapy drugs. The appearance of targeted drugs has completely changed the attitude towards such a dangerous and formidable biological subtype as HER2+. Tumors with this molecular genetic subtype, when anti-HER2 agents appeared, began to actively respond to drug therapy and achieve complete pathomorphological responses (pCR). Patients with pCR have a better prognosis compared to patients with residual disease after neoadjuvant treatment. This article presents central studies that have historically changed the approach to the treatment of early HER2+ breast cancer, thanks to which, today, they are tools for the professional activity of an oncologist.
Keywords:HER2-positive breast cancer, anti-HER2 blockade, pCR, neoadjuvant drug therapy, RCB, FISH hybridization
|
|
| |
|
Read the full article …
|
Citation link:
Krivokhizhin I. V., Parsadanyan A. M., Stepanyan A. A. FUNDAMENTAL RESEARCH THAT CHANGED THE APPROACH TO NEOADJUVANT TREATMENT OF EARLY HER2-POSITIVE BREAST CANCER // Современная наука: актуальные проблемы теории и практики. Серия: Естественные и Технические Науки. -2023. -№08/2. -С. 168-171 DOI 10.37882/2223-2966.2023.8-2.16 |
|
|
